Profound response to venetoclax monotherapy in a patient with BCL-2 positive relapsed multiple myeloma and extramedullary CNS manifestations.

In summary, venetoclax might represent a safe and effective treatment option for RRMM patients with BCL-2 positive CNS-EMD and further research in these rare but very difficult-to-treat patients is warranted. In this situation we evaluated venetoclax as a treatment option and analyzed marrow- and CSF-derived myeloma cells for BCL-2 expression by routine immunohistochemistry (IHC). Extramedullary disease (EMD) occurs as a secondary event in 5-10% of patients with relapsed/refractory multiple myeloma (RRMM) and prognosis is unfavorable [[1]]. [Extracted from the article]